DrugBiological
Poly ICLC clinical trials
Also written Hiltonol and NSC-301463.
- studies test it
- 54
- open now
- 2
- in phase 3
- 0
- first study started
- 2002
Keep track of what changes. Save the poly ICLC studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Name
Development codes
Combined with it in one product
Studies by the year they started
54 studies that test it; most in 2014 (6)
| Year | Studies |
|---|---|
| 2002 | 1 |
| 2003 | 1 |
| 2006 | 1 |
| 2007 | 2 |
| 2008 | 2 |
| 2009 | 5 |
| 2010 | 3 |
| 2011 | 4 |
| 2012 | 3 |
| 2013 | 2 |
| 2014 | 6 |
| 2015 | 4 |
| 2016 | 1 |
| 2017 | 2 |
| 2018 | 4 |
| 2019 | 3 |
| 2021 | 2 |
| 2022 | 4 |
| 2023 | 2 |
| 2024 | 2 |
By phase
A phase 1/2 study counts in both.
- Early Phase 1
- 2
- Phase 1
- 41
- Phase 2
- 21
- No phase
- 1
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 6 · Other 48
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (5) · Washington University School of Medicine (4) · Rockefeller University (3) · University Hospital, Geneva (2) · H. Lee Moffitt Cancer Center and Research Institute (2) · Nina Bhardwaj (2) · Medical University of South Carolina (2) · Craig L Slingluff, Jr (2)
Often tested with
Tested in the same studies.
Pembrolizumab (4) · flt3 ligand protein (3) · Rasdegafusp alfa (3) · Peptides (2) · Nivolumab (2) · IMA950 (2) · CDX-301 (2) · Protein Subunit Vaccines (2)
Studies
Open first, then newest update. How each study uses poly ICLC is read from its arms, and is right about nine times in ten.
Testing it · 54
- Personalized Neo-Antigen Peptide Vaccine for the Treatment of Stage IIIC-IV Melanoma, Hormone Receptor Positive HER2 Negative Metastatic Refractory Breast Cancer or Stage III-IV Non-Small Cell Lung CancerRecruitingPhase 1Fred Hutchinson Cancer CenterNCT05098210Written as Poly ICLC
- Intratumoral and Systemic Hiltonol® (Poly-ICLC) in Prostate Cancer Patients on Active SurveillanceRecruitingPhase 2Ashutosh Kumar TewariNCT06343077Written as Poly-ICLC intramuscular (IM) injection
- Mutant KRAS -Targeted Long Peptide Vaccine for Patients at High Risk of Developing Pancreatic CancerActive, not recruitingPhase 1Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsNCT05013216Written as Cohort A: Patients at high risk of developing pancreatic cancer.
- Safety and Immunogenicity of Personalized Genomic Vaccine and Tumor Treating Fields (TTFields) to Treat GlioblastomaActive, not recruitingPhase 1Adilia HormigoNCT03223103Written as Poly-ICLC
- Vaccination With Flt3L, Radiation, and Poly-ICLCCompletedPhase 1/2Icahn School of Medicine at Mount SinaiNCT03789097Written as Poly ICLC
- Neoantigen Vaccines in Pancreatic Cancer in the Window Prior to SurgeryCompletedPhase 1Washington University School of MedicineNCT05111353Written as Poly-ICLC
- ETAPA I: Peptide-based Tumor Associated Antigen Vaccine in GBMActive, not recruitingPhase 1Mustafa Khasraw, MBChB, MD, FRCP, FRACPNCT05283109Written as Hiltonol
- DEC-205/NY-ESO-1 Fusion Protein CDX-1401, Poly ICLC, Decitabine, and Nivolumab in Treating Patients With Myelodysplastic Syndrome or Acute Myeloid LeukemiaCompletedPhase 1Roswell Park Cancer InstituteNCT03358719Written as Poly ICLC
- A Phase I Study With a Personalized NeoAntigen Cancer Vaccine in MelanomaCompletedPhase 1Patrick Ott, MD, PhDNCT01970358Written as Poly-ICLC
- Focused Ultrasound Ablation and PD-1 Antibody Blockade in Advanced Solid TumorsTerminatedPhase 1Craig L Slingluff, JrNCT04116320Written as Poly ICLC
- Pembrolizumab in Association With the IMA950/Poly-ICLC for Relapsing GlioblastomaCompletedPhase 1/2University Hospital, GenevaNCT03665545Written as IMA950/Poly-ICLC
- A Phase II Trial of Poly-ICLC for Low-Grade GliomasTerminatedPhase 2University of Alabama at BirminghamNCT04544007Written as Poly ICLC
- Safety and Efficacy Study of SL-701, a Glioma-Associated Antigen Vaccine To Treat Recurrent Glioblastoma MultiformeCompletedPhase 1/2Stemline Therapeutics, Inc.NCT02078648Written as SL-701; poly-ICLC (polyinosinic-polycytidylic acid stabilized with polylysine and carboxymethyl cellulose)
- A Pilot Study of Glioma Associated Antigen Vaccines in Conjunction with Poly-ICLC in Pediatric GliomasCompletedPhase 1James FelkerNCT01130077Written as Poly-ICLC
- Harnessing Allo-immunity to Enhance Immune Checkpoint Inhibitor Responses in Advanced NSCLCWithdrawnPhase 1/2VA Office of Research and DevelopmentNCT06064279Written as Poly ICLC
- Pembrolizumab + Poly-ICLC in MRP Colon CancerCompletedPhase 1/2Asha NayakNCT02834052Written as Poly-ICLC
- Platform Study for Prostate Researching Translational Endpoints Correlated to Response to Inform Use of Novel CombinationsCompletedPhase 1Parker Institute for Cancer ImmunotherapyNCT03835533Written as Poly-ICLC (Cohort B)
- A Trial of Poly-ICLC in the Management of Recurrent Pediatric Low Grade GliomasCompletedPhase 2Wake Forest University Health SciencesNCT01188096Written as Poly ICLC
- Neoantigen-Targeted Vaccine Combined With Anti-PD-1 Antibody for Patients With Stage IV MMR-p Colon and Pancreatic Ductal CancerWithdrawnPhase 1Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsNCT04799431Written as Neoantigen Vaccine with Poly-ICLC adjuvant
- In Situ Vaccine for Low-Grade Lymphoma: Combination of Intratumoral Flt3L and Poly-ICLC With Low-Dose RadiotherapyCompletedPhase 1/2Joshua BrodyNCT01976585Written as Poly-ICLC
See all 54 studies that test poly ICLC →
Given in every arm · 36 — poly ICLC is usual care beside what is tested
- Prototype DAA/TAA Vaccine Targeting MUC1 for Immune Interception and Prevention in Ductal Carcinoma In SituRecruitingPhase 1Finn, Olivera, PhDNCT06218303Written as Hiltonol®
- Testing the Addition of an Individualized Vaccine to Durvalumab and Tremelimumab and Chemotherapy in Patients With Metastatic Triple Negative Breast CancerRecruitingPhase 2National Cancer Institute (NCI)NCT03606967Written as Poly ICLC
- Personalized Cancer Vaccine (PCV) Strategy in Patients With Solid Tumors and Molecular Residual DiseaseRecruitingPhase 1Washington University School of MedicineNCT06529822Written as Poly ICLC
- Personalized Cancer Vaccine (PCV) Strategy in Triple Negative Breast Cancer PatientsNot yet recruitingPhase 1Washington University School of MedicineNCT07300475Written as poly-ICLC
- KRAS-Targeted Vaccine Combined With Balstilimab and Botensilimab for Patients With Stage IV MMR-p Colorectal Cancer and Pancreatic Ductal CancerRecruitingPhase 1Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsNCT06411691Written as KRAS Vaccine with Poly-ICLC adjuvant
- A Personalized Neoantigen Cancer Vaccine in Treatment Naïve, Asymptomatic Patients With IGHV Unmutated CLL.RecruitingPhase 1Dana-Farber Cancer InstituteNCT03219450Written as NeoVax
- Atezolizumab, Guadecitabine, and CDX-1401 Vaccine in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal CancerTerminatedPhase 1/2National Cancer Institute (NCI)NCT03206047Written as Poly ICLC
- NeoVax With Nivolumab in Patients With Ovarian CancerActive, not recruitingPhase 1Dana-Farber Cancer InstituteNCT04024878Written as NeoVax
- A Study of PVX-410, a Cancer Vaccine, and Citarinostat +/- Lenalidomide for Smoldering MMActive, not recruitingPhase 1Massachusetts General HospitalNCT02886065Written as Hiltonol
- Mutant CALR-peptide Based Vaccine in Patients With Mutated CALR Myeloproliferative NeoplasmActive, not recruitingPhase 1Marina KremyanskayaNCT05025488Written as Poly ICLC
- Pembrolizumab and a Vaccine (ATL-DC) for the Treatment of Surgically Accessible Recurrent GlioblastomaCompletedPhase 1Jonsson Comprehensive Cancer CenterNCT04201873Written as Poly ICLC
- In Situ Immunomodulation With CDX-301, Radiation Therapy, CDX-1140 and Poly-ICLC in Patients w/ Unresectable and Metastatic Solid TumorsActive, not recruitingPhase 1University of Southern CaliforniaNCT04616248Written as Poly ICLC
- Personalized NeoAntigen Cancer Vaccine w RT Plus Pembrolizumab for Patients With Newly Diagnosed GBMActive, not recruitingPhase 1Dana-Farber Cancer InstituteNCT02287428Written as Poly-ICLC
- NeoVax + CDX-301 and Nivolumab or Pembrolizumab in MelanomaActive, not recruitingPhase 1Dana-Farber Cancer InstituteNCT04930783Written as NEOVAX
- A Vaccine (Neoantigen-Targeted ppDC) for the Treatment of H3 G34-mutant Diffuse Hemispheric GliomaActive, not recruitingPhase 1Jonsson Comprehensive Cancer CenterNCT06342908Written as Poly ICLC
- NeoVax Plus Ipilimumab in Renal Cell CarcinomaActive, not recruitingPhase 1Patrick Ott, MD, PhDNCT02950766Written as NeoVax
- The Safety and Tolerability of PGV001-based Personalized Multi-peptide Vaccines in the Adjuvant Setting.Active, not recruitingPhase 1Ashutosh Kumar TewariNCT05010200Written as Poly-ICLC
- Adjuvant PVX-410 Vaccine and Durvalumab in Stage II/III Triple Negative Breast CancerActive, not recruitingPhase 1Massachusetts General HospitalNCT02826434Written as Hiltonol
- Peptide-Pulsed Dendritic Cell Vaccination in Combination With Nivolumab and Ipilimumab for the Treatment of Recurrent and/or Progressive Diffuse Hemispheric Glioma, H3 G34-mutantWithdrawnPhase 1Jonsson Comprehensive Cancer CenterNCT05457959Written as Poly ICLC
- Neoantigen Peptide Vaccine Strategy in Pancreatic Cancer Patients Following Surgical Resection and Adjuvant ChemotherapyTerminatedPhase 1Washington University School of MedicineNCT03956056Written as Poly ICLC
Showing 20 of 36.
Codes
What other systems call poly ICLC · ClinicalTrials.gg INT002713
- MeSH (NLM) C019531poly ICLCConfirmed ClinicalTrials.gov, NLM
- UNII (FDA) 7KYP9TKT70HILTONOLConfirmed FDA, NLM
- NCI Thesaurus C1198Poly ICLCOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C019531 | poly ICLC | Confirmed ClinicalTrials.gov, NLM |
| UNII (FDA) | 7KYP9TKT70 | HILTONOL | Confirmed FDA, NLM |
| NCI Thesaurus | C1198 | Poly ICLC | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.